Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population
Objective: Prior evaluations of ulcerative colitis (UC)-related costs are dated or encompassed limited follow-up. This study assessed the incremental direct and indirect work loss-related costs of privately-insured patients with UC in the United States, overall and in specific subgroups.Methods: In this retrospective matched cohort study, the OptumHealth Care Solutions, Inc (formerly Optum Health Reporting and Insights employer) database (01 January 1999-31 March 2017) was used to identify adult patients with ≥2 claims for UC, who were matched 1:5 to patients with no claims for inflammatory bowel disease (IBD). UC subgroups were identified based on indicators during the observation period (i.e. use of biologics, opioids, or corticosteroids; UC-related surgery; moderate-to-severe disease; UC-related comorbidities). Healthcare resource utilization (HRU), work loss days, and direct and work loss-related costs were compared between matched cohorts. Descriptive analyses of direct and work loss-related costs were conducted within each UC subgroup.Results: Compared to the non-IBD cohort (n = 46,765), the UC cohort (n = 9353) incurred higher HRU, including 128% more inpatients visits, resulting in $11,029 higher direct costs per patient per year (PPPY; $7170 vs. $18,198; p < .001). Patients in the UC cohort also incurred more work loss days, resulting in $2142 higher work loss-related costs PPPY ($3165 vs. $5307; p < .001). Direct and work loss-related costs were particularly high in the UC subgroups, with patients undergoing UC-related surgery incurring the highest costs.Conclusions: Over ∼5 years follow-up, patients with UC had significantly higher all-cause direct healthcare and indirect work loss-related costs compared to matched patients without IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Current medical research and opinion - 36(2020), 8 vom: 18. Aug., Seite 1285-1294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pilon, Dominic [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic burden |
|---|
| Anmerkungen: |
Date Completed 01.06.2021 Date Revised 01.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03007995.2020.1771293 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310095107 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310095107 | ||
| 003 | DE-627 | ||
| 005 | 20231225135339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03007995.2020.1771293 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310095107 | ||
| 035 | |a (NLM)32427006 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pilon, Dominic |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2021 | ||
| 500 | |a Date Revised 01.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: Prior evaluations of ulcerative colitis (UC)-related costs are dated or encompassed limited follow-up. This study assessed the incremental direct and indirect work loss-related costs of privately-insured patients with UC in the United States, overall and in specific subgroups.Methods: In this retrospective matched cohort study, the OptumHealth Care Solutions, Inc (formerly Optum Health Reporting and Insights employer) database (01 January 1999-31 March 2017) was used to identify adult patients with ≥2 claims for UC, who were matched 1:5 to patients with no claims for inflammatory bowel disease (IBD). UC subgroups were identified based on indicators during the observation period (i.e. use of biologics, opioids, or corticosteroids; UC-related surgery; moderate-to-severe disease; UC-related comorbidities). Healthcare resource utilization (HRU), work loss days, and direct and work loss-related costs were compared between matched cohorts. Descriptive analyses of direct and work loss-related costs were conducted within each UC subgroup.Results: Compared to the non-IBD cohort (n = 46,765), the UC cohort (n = 9353) incurred higher HRU, including 128% more inpatients visits, resulting in $11,029 higher direct costs per patient per year (PPPY; $7170 vs. $18,198; p < .001). Patients in the UC cohort also incurred more work loss days, resulting in $2142 higher work loss-related costs PPPY ($3165 vs. $5307; p < .001). Direct and work loss-related costs were particularly high in the UC subgroups, with patients undergoing UC-related surgery incurring the highest costs.Conclusions: Over ∼5 years follow-up, patients with UC had significantly higher all-cause direct healthcare and indirect work loss-related costs compared to matched patients without IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 4 | |a chronic burden | |
| 650 | 4 | |a colon | |
| 650 | 4 | |a costs | |
| 650 | 4 | |a real-world data | |
| 650 | 4 | |a work loss | |
| 700 | 1 | |a Ding, Zhijie |e verfasserin |4 aut | |
| 700 | 1 | |a Muser, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Obando, Camilo |e verfasserin |4 aut | |
| 700 | 1 | |a Voelker, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Manceur, Ameur M |e verfasserin |4 aut | |
| 700 | 1 | |a Kinkead, Frederic |e verfasserin |4 aut | |
| 700 | 1 | |a Lafeuille, Marie-Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Lefebvre, Patrick |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medical research and opinion |d 1972 |g 36(2020), 8 vom: 18. Aug., Seite 1285-1294 |w (DE-627)NLM000081019 |x 1473-4877 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2020 |g number:8 |g day:18 |g month:08 |g pages:1285-1294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03007995.2020.1771293 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2020 |e 8 |b 18 |c 08 |h 1285-1294 | ||